Table 2.
Prior cancer treatment and transplant related information for Allo-SCT survivors.
| N = 14 | |
|---|---|
| Time since transplantation, years | 6.5 (2—20) |
| Hematological malignancy, n (%) | |
| Acute lymphoblastic leukaemia | 6 (43) |
| Acute myeloid leukaemia | 3 (21) |
| Non-Hodgkin lymphoma | 2 (14) |
| Chronic lymphocytic leukaemia | 1 (7) |
| Chronic myeloid leukaemia | 1 (7) |
| Multiple myeloma | 1 (7) |
| Pre-transplant anti-cancer treatment, n (%) | |
| No prior treatment | 1 (7) |
| Chemotherapy | 12 (86) |
| Immunotherapy | 6 (43) |
| Targeted therapy | 3 (21) |
| Autologous SCT | 1 (7) |
| Transplant donor, n (%) | |
| Unrelated | 8 (57) |
| Related | 6 (43) |
| Transplant graft source, n (%) | |
| Peripheral blood | 9 (64) |
| Bone marrow | 5 (36) |
| Transplant conditioning intensity, n (%) | |
| Myeloablative | 11 (79) |
| Reduced intensity | 3 (21) |
| Transplant conditioning regimen, n (%) | |
| Cyclophosphamide/TBI | 10 (71) |
| Fludarabine/Melphalan | 1 (7) |
| Fludarabine/Melphalan/Campath | 1 (7) |
| Fludarabine | 1 (7) |
| Busulfan/Cyclophosphamide | 1 (7) |
| GvHD prophylaxis, n (%) | |
| Methotrexate/ciclosporin | 11 (79) |
| Post-transplant Cyclophosphamide/ciclosporin | 1 (7) |
| Ciclosporin/mycophenolate | 1 (7) |
| Ciclosporin | 1 (7) |
| History of GvHD, n (%) | |
| No | 6 (43) |
| Yes | 8 (57) |
| Length of hospital stay, days | 25 ± 4 |
Data are n (%), mean ± SD, or median (range). Abbreviations: GvHD graft-vs-host disease; TBI total body irradiation